1
The National Institute for Health and Care Excellence (NICE) has reaffirmed its stance against recommending Alzheimer’s treatments donanemab and lecanemab for NHS use, citing insufficient cost-effectiveness.
Despite additional evidence submitted by manufacturers, the independent appraisal committee concluded that the treatments do not provide enough benefit to justify their significant cost.
NICE first raised concerns about these treatments last year, determining that their clinical benefits did not outweigh the financial burden they would place on the NHS.
Read Next: Denali Therapeutics Ends ALS …
